 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Reliant Pharmaceuticals" – news ·newspapers ·books ·scholar ·JSTOR(June 2015) (Learn how and when to remove this message) |
| Industry | Pharmaceuticals |
|---|---|
| Defunct | December 2007 (2007-12) |
| Fate | Acquired byGlaxoSmithKline |
Key people | Joseph J. Krivulka (co-founder) |
Reliant Pharmaceuticals was a company purchased by GlaxoSmithKline in December 2007 for $1.65B.[1] Co-founded by Joseph J. Krivulka.
It was known for six major products, includingLovaza (Omega-3),Axid (H2 blocker), Dynacirc CR (calcium channel blocker), Antara (fenofibrate),InnoPran XL (beta blocker), Lescol XL (Fluvastatin), and Rythmol SR (Class IC anti-arrhythmic).
Reliant Pharmaceuticals, Inc. was a pharmaceutical company that specialized in the development, commercialization and marketing of prescription therapeutic products. Reliant marketed six cardiovascular products in the United States and focused on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliants' sales force consisted of approximately 650 sales and marketing professionals nationwide.
In 2007, Reliant Pharmaceuticals was acquired by GSK for $1.65 billion in cash, after Reliant recorded net sales of $341 million in the nine months leading to September 30, 2007.[2] The Lovaza drug accounted for 60% of the sales of the company for that period.[3]
 | This article about amedical,pharmaceutical orbiotechnological corporation or company is astub. You can help Wikipedia byadding missing information. |
